DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.
Metrics to compare | 34D | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship34DPeersSector | |
---|---|---|---|---|
P/E Ratio | 30.7x | 21.8x | −0.7x | |
PEG Ratio | - | 0.47 | 0.00 | |
Price/Book | 3.6x | 2.6x | 2.6x | |
Price / LTM Sales | 4.9x | 3.2x | 3.2x | |
Upside (Analyst Target) | - | 20.1% | 45.2% | |
Fair Value Upside | Unlock | 13.0% | 7.0% | Unlock |